Travere Therapeutics (NASDAQ:TVTX) EVP Jula Inrig Sells 44,674 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) EVP Jula Inrig sold 44,674 shares of Travere Therapeutics stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total transaction of $2,784,977.16. Following the sale, the executive vice president owned 100,491 shares in the company, valued at approximately $6,264,608.94. This trade represents a 30.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

NASDAQ:TVTX opened at $64.74 on Friday. Travere Therapeutics, Inc. has a 12-month low of $22.06 and a 12-month high of $68.73. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58. The firm has a market capitalization of $6.10 billion, a PE ratio of -140.74 and a beta of 1.05. The firm has a 50-day moving average price of $61.63 and a 200 day moving average price of $48.50.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. The firm had revenue of $169.58 million during the quarter, compared to analysts’ expectations of $157.27 million. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. The company’s revenue for the quarter was up 48.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.13 earnings per share. Research analysts anticipate that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after purchasing an additional 211 shares during the last quarter. Fifth Third Bancorp acquired a new position in Travere Therapeutics during the 1st quarter worth about $35,000. Allworth Financial LP bought a new stake in Travere Therapeutics during the 2nd quarter worth about $47,000. Integrated Wealth Concepts LLC bought a new stake in Travere Therapeutics during the 2nd quarter worth about $70,000. Finally, IFP Advisors Inc increased its position in Travere Therapeutics by 11,770.0% in the 4th quarter. IFP Advisors Inc now owns 2,374 shares of the company’s stock valued at $91,000 after acquiring an additional 2,354 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on TVTX shares. HC Wainwright boosted their price target on Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Citigroup lifted their price objective on Travere Therapeutics from $70.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating on shares of Travere Therapeutics in a report on Monday, August 17th. TD Cowen increased their target price on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Wedbush lifted their price target on shares of Travere Therapeutics from $61.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $68.00.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.